June 02, 2025 a 12:38 pm
COR: Analysts Ratings - Cencora, Inc.
Cencora, Inc. has shown a stable performance in the stock market, appealing to pharmaceutical distributors and healthcare providers. Recent analyst ratings suggest a cautious but stable outlook with most recommendations being in the 'Buy' category. The company's comprehensive network in both U.S. and international markets provides a robust foundation for growth.
Historical Stock Grades
The analysis of the latest data indicates a predominance of 'Buy' ratings, suggesting a stable yet optimistic perspective on Cencora's performance. The presence of minimal 'Strong Buy' and 'Strong Sell' ratings highlight a consensus towards a balanced outlook.
| Rating | Number of Analysts | Score |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 9 | |
| Hold | 6 | |
| Sell | 0 | |
| Strong Sell | 1 |
Sentiment development
The stable ratio of 'Buy' ratings over recent months suggests equilibrium in market sentiment. However, the historical 'Strong Buy' ratings have decreased, indicating cautious optimism among analysts.
- Overall ratings have remained consistent month to month.
- 'Strong Buy' ratings are becoming less dominant.
- 'Hold' ratings have seen minor fluctuations but mostly stayed stable.
Percentage trends
Analysis of percentage trends highlights a modest inclination towards 'Buy' over the months, maintaining a strong sentiment of confidence.
- 'Buy' ratings typically comprise around 60% of all ratings.
- There has been a noticeable decline in 'Strong Buy' percentages since late 2024.
- Overall skepticism remains low with minimal 'Sell' and 'Strong Sell' ratings.
Latest Analyst Recommendations
Recent maintenance of ratings by analysts indicates a consistent belief in Cencora's performance, without major shifts in sentiment.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-05-08 | Outperform | Outperform | Baird |
| 2025-05-08 | Buy | Buy | Citigroup |
| 2025-04-29 | Buy | Buy | UBS |
| 2025-04-11 | Neutral | Neutral | B of A Securities |
| 2025-03-14 | Equal Weight | Equal Weight | Wells Fargo |
Analyst Recommendations with Change of Opinion
Significant changes in recommendations occurred in mid-2022, showing a shift in sentiment from 'Neutral' to 'Buy', and 'Outperform' to 'In Line', reflecting some adjustments in analysts' perspectives.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2022-10-11 | Buy | Neutral | B of A Securities |
| 2022-10-10 | Buy | Neutral | B of A Securities |
| 2022-07-11 | In Line | Outperform | Evercore ISI Group |
| 2022-07-10 | In Line | Outperform | Evercore ISI Group |
| 2022-06-07 | Buy | Hold | Deutsche Bank |
Interpretation
The current analyst sentiment regarding Cencora, Inc., implies a stable, long-term growth trajectory. Consistent 'Buy' ratings suggest confidence in the company's market strategies and operational efficiency. Although the decline in 'Strong Buy' ratings might indicate cautious optimism, the limited presence of 'Sell' ratings confirms the company's resilience in a competitive pharmaceutical market context. Analysts appear to maintain a steady, favorable outlook, reflecting a balanced confidence in future performance with minimal volatility.
Conclusion
The analysis of Cencora, Inc.'s ratings portrays a steady outlook characterized by consistent 'Buy' recommendations. Although there has been a slight decline in more optimistic 'Strong Buy' opinions, the overall sentiment remains strongly positive towards potential growth and stability. Analysts seem to favor Cencora's extensive distribution network and diversified service offerings as key drivers for future success. It is crucial for investors to consider ongoing industry trends and company developments that may influence future analyst recommendations.